Literature DB >> 29238589

Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells.

Stefano Gigli1, Luisa Seguella1, Marcella Pesce2, Eugenia Bruzzese3, Alessandra D'Alessandro2, Rosario Cuomo2, Luca Steardo1, Giovanni Sarnelli2, Giuseppe Esposito1.   

Abstract

BACKGROUND: Clostridium difficile toxin A is responsible for colonic damage observed in infected patients. Drugs able to restore Clostridium difficile toxin A-induced toxicity have the potential to improve the recovery of infected patients. Cannabidiol is a non-psychotropic component of Cannabis sativa, which has been demonstrated to protect enterocytes against chemical and/or inflammatory damage and to restore intestinal mucosa integrity.
OBJECTIVE: The purpose of this study was to evaluate (a) the anti-apoptotic effect and (b) the mechanisms by which cannabidiol protects mucosal integrity in Caco-2 cells exposed to Clostridium difficile toxin A.
METHODS: Caco-2 cells were exposed to Clostridium difficile toxin A (30 ng/ml), with or without cannabidiol (10-7-10-9 M), in the presence of the specific antagonist AM251 (10-7 M). Cytotoxicity assay, transepithelial electrical resistence measurements, immunofluorescence analysis and immunoblot analysis were performed in the different experimental conditions.
RESULTS: Clostridium difficile toxin A significantly decreased Caco-2 cells' viability and reduced transepithelial electrical resistence values and RhoA guanosine triphosphate (GTP), bax, zonula occludens-1 and occludin protein expression, respectively. All these effects were significantly and concentration-dependently inhibited by cannabidiol, whose effects were completely abolished in the presence of the cannabinoid receptor type 1 (CB1) antagonist, AM251.
CONCLUSIONS: Cannabidiol improved Clostridium difficile toxin A-induced damage in Caco-2 cells, by inhibiting the apoptotic process and restoring the intestinal barrier integrity, through the involvement of the CB1 receptor.

Entities:  

Keywords:  Clostridium difficile; cannabidiol; cannabinoids; clostridium difficile toxin A; intestinal permeability

Year:  2017        PMID: 29238589      PMCID: PMC5721977          DOI: 10.1177/2050640617698622

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  35 in total

1.  Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells.

Authors:  Gerly A C Brito; Jun Fujji; Benedito A Carneiro-Filho; Aldo A M Lima; Tom Obrig; Richard L Guerrant
Journal:  J Infect Dis       Date:  2002-10-29       Impact factor: 5.226

Review 2.  Clostridium difficile infection.

Authors:  Daniel A Leffler; J Thomas Lamont
Journal:  N Engl J Med       Date:  2015-04-16       Impact factor: 91.245

3.  Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability.

Authors:  A Alhamoruni; A C Lee; K L Wright; M Larvin; S E O'Sullivan
Journal:  J Pharmacol Exp Ther       Date:  2010-06-30       Impact factor: 4.030

Review 4.  Safety and side effects of cannabidiol, a Cannabis sativa constituent.

Authors:  Mateus Machado Bergamaschi; Regina Helena Costa Queiroz; Antonio Waldo Zuardi; José Alexandre S Crippa
Journal:  Curr Drug Saf       Date:  2011-09-01

Review 5.  Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.

Authors:  S E O'Sullivan; D A Kendall
Journal:  Immunobiology       Date:  2009-10-14       Impact factor: 3.144

6.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

Authors:  A J Hampson; M Grimaldi; J Axelrod; D Wink
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

7.  The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins.

Authors:  I Just; M Wilm; J Selzer; G Rex; C von Eichel-Streiber; M Mann; K Aktories
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

Review 8.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

9.  Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement.

Authors:  Giuseppe Esposito; Caterina Scuderi; Marta Valenza; Giuseppina Ines Togna; Valentina Latina; Daniele De Filippis; Mariateresa Cipriano; Maria Rosaria Carratù; Teresa Iuvone; Luca Steardo
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

10.  Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.

Authors:  Daniele De Filippis; Giuseppe Esposito; Carla Cirillo; Mariateresa Cipriano; Benedicte Y De Winter; Caterina Scuderi; Giovanni Sarnelli; Rosario Cuomo; Luca Steardo; Joris G De Man; Teresa Iuvone
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

View more
  11 in total

1.  Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor.

Authors:  Rossella Fonnesu; Venkata Bala Sai Chaitanya Thunuguntla; Ganesh Kumar Veeramachaneni; Jayakumar Singh Bondili; Veronica La Rocca; Carolina Filipponi; Pietro Giorgio Spezia; Maria Sidoti; Erika Plicanti; Paola Quaranta; Giulia Freer; Mauro Pistello; Michael Lee Mathai; Michele Lai
Journal:  Viruses       Date:  2022-05-17       Impact factor: 5.818

2.  Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications.

Authors:  Loredana Raciti; Francesca Antonia Arcadi; Rocco Salvatore Calabrò
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

3.  Cannabinoid receptor 2 agonist promotes parameters implicated in mucosal healing in patients with inflammatory bowel disease.

Authors:  Shelly Tartakover Matalon; Yehuda Ringel; Fred Konikoff; Liat Drucker; Shaul Pery; Timna Naftali
Journal:  United European Gastroenterol J       Date:  2019-11-14       Impact factor: 4.623

4.  A Palmitoylethanolamide Producing Lactobacillus paracasei Improves Clostridium difficile Toxin A-Induced Colitis.

Authors:  Giuseppe Esposito; Chiara Corpetti; Marcella Pesce; Luisa Seguella; Giuseppe Annunziata; Alessandro Del Re; Martina Vincenzi; Roberta Lattanzi; Jie Lu; Walter Sanseverino; Giovanni Sarnelli
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

5.  Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line.

Authors:  Chiara Corpetti; Alessandro Del Re; Luisa Seguella; Irene Palenca; Sara Rurgo; Barbara De Conno; Marcella Pesce; Giovanni Sarnelli; Giuseppe Esposito
Journal:  Phytother Res       Date:  2021-10-12       Impact factor: 6.388

6.  Clostridium difficile fecal toxin level is associated with disease severity and prognosis.

Authors:  Nathaniel A Cohen; Tamar Miller; Wasef Na'aminh; Keren Hod; Amos Adler; Daniel Cohen; Hanan Guzner-Gur; Erwin Santo; Zamir Halpern; Yehuda Carmeli; Nitsan Maharshak
Journal:  United European Gastroenterol J       Date:  2017-12-21       Impact factor: 4.623

7.  Protective effects of Δ9 -tetrahydrocannabinol against enterotoxin-induced acute respiratory distress syndrome are mediated by modulation of microbiota.

Authors:  Amira Mohammed; Hasan K Alghetaa; Juhua Zhou; Saurabh Chatterjee; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Br J Pharmacol       Date:  2020-10-08       Impact factor: 8.739

Review 8.  Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.

Authors:  Cristian Scheau; Constantin Caruntu; Ioana Anca Badarau; Andreea-Elena Scheau; Anca Oana Docea; Daniela Calina; Ana Caruntu
Journal:  J Pers Med       Date:  2021-05-31

9.  Frontiers in antibiotic alternatives for Clostridioides difficile infection.

Authors:  Matthew Phanchana; Phurt Harnvoravongchai; Supapit Wongkuna; Tanaporn Phetruen; Wichuda Phothichaisri; Supakan Panturat; Methinee Pipatthana; Sitthivut Charoensutthivarakul; Surang Chankhamhaengdecha; Tavan Janvilisri
Journal:  World J Gastroenterol       Date:  2021-11-14       Impact factor: 5.742

Review 10.  Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges.

Authors:  Miguel Olivas-Aguirre; Liliana Torres-López; Kathya Villatoro-Gómez; Sonia Mayra Perez-Tapia; Igor Pottosin; Oxana Dobrovinskaya
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.